Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as an oral tablet for oral use. It treats serious Gram‑positive bacterial infections, including MRSA and VRE, in adult patients when other antibiotics are ineffective. It is indicated for infections such as community‑acquired bacterial pneumonia and skin and soft‑tissue infections, providing an oral alternative to intravenous therapy.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics across EU and other markets.

Linezolid is an oxazolidinone antibiotic used to treat serious Gram‑positive bacterial infections. - Gram‑positive bacterial infections: effective against a broad range of susceptible organisms, reducing bacterial load. - Methicillin‑resistant Staphylococcus aureus (MRSA): provides oral therapy for skin, soft tissue and pneumonia caused by MRSA. - Vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for infections caused by VRE. - Community‑acquired bacterial pneumonia: helps resolve pneumonia caused by susceptible Gram‑positive pathogens. - Skin and soft tissue infections: treats cellulitis, abscesses and other soft‑tissue infections due to susceptible organisms.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: skin erythema or mild itching.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Peripheral neuropathy: nerve pain or sensory loss. - Lactic acidosis: buildup of lactate causing metabolic disturbance.

When prescribing Linezolid, clinicians should observe several safety considerations to minimize risks. - Monitor blood counts: regular CBC testing to detect myelosuppression. - Assess renal and hepatic function: adjust use in severe impairment. - Avoid prolonged therapy: limit duration to reduce risk of neuropathy. - Review concomitant serotonergic drugs: potential for serotonin syndrome. - Pregnancy category C: use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Linezolid interacts with several medicines; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs), MAO inhibitors, tricyclic antidepressants: risk of serotonin syndrome. - Rifampicin: reduces linezolid plasma concentrations, decreasing efficacy. - Tyramine‑rich foods (when combined with MAO inhibitors): may cause hypertensive crisis.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Ethanol: potential disulfiram‑like reaction, advise caution. - Didanosine: increased risk of peripheral neuropathy, monitor symptoms.